184 related articles for article (PubMed ID: 24924199)
1. Role of MAPK in oncolytic herpes viral therapy in triple-negative breast cancer.
Gholami S; Chen CH; Gao S; Lou E; Fujisawa S; Carson J; Nnoli JE; Chou TC; Bromberg J; Fong Y
Cancer Gene Ther; 2014 Jul; 21(7):283-9. PubMed ID: 24924199
[TBL] [Abstract][Full Text] [Related]
2. A novel vaccinia virus with dual oncolytic and anti-angiogenic therapeutic effects against triple-negative breast cancer.
Gholami S; Marano A; Chen NG; Aguilar RJ; Frentzen A; Chen CH; Lou E; Fujisawa S; Eveno C; Belin L; Zanzonico P; Szalay A; Fong Y
Breast Cancer Res Treat; 2014 Dec; 148(3):489-99. PubMed ID: 25391896
[TBL] [Abstract][Full Text] [Related]
3. 5-fluorouracil and gemcitabine potentiate the efficacy of oncolytic herpes viral gene therapy in the treatment of pancreatic cancer.
Eisenberg DP; Adusumilli PS; Hendershott KJ; Yu Z; Mullerad M; Chan MK; Chou TC; Fong Y
J Gastrointest Surg; 2005 Nov; 9(8):1068-77; discussion 1077-9. PubMed ID: 16269377
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic herpes simplex virus treatment of metastatic breast cancer.
Wang J; Hu P; Zeng M; Rabkin SD; Liu R
Int J Oncol; 2012 Mar; 40(3):757-63. PubMed ID: 22108767
[TBL] [Abstract][Full Text] [Related]
5. The replication-competent oncolytic herpes simplex mutant virus NV1066 is effective in the treatment of esophageal cancer.
Stiles BM; Bhargava A; Adusumilli PS; Stanziale SF; Kim TH; Rusch VW; Fong Y
Surgery; 2003 Aug; 134(2):357-64. PubMed ID: 12947341
[TBL] [Abstract][Full Text] [Related]
6. Cisplatin-induced GADD34 upregulation potentiates oncolytic viral therapy in the treatment of malignant pleural mesothelioma.
Adusumilli PS; Chan MK; Chun YS; Hezel M; Chou TC; Rusch VW; Fong Y
Cancer Biol Ther; 2006 Jan; 5(1):48-53. PubMed ID: 16294031
[TBL] [Abstract][Full Text] [Related]
7. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
Vázquez R; Riveiro ME; Astorgues-Xerri L; Odore E; Rezai K; Erba E; Panini N; Rinaldi A; Kwee I; Beltrame L; Bekradda M; Cvitkovic E; Bertoni F; Frapolli R; D'Incalci M
Oncotarget; 2017 Jan; 8(5):7598-7613. PubMed ID: 27935867
[TBL] [Abstract][Full Text] [Related]
8. Enhancing Therapeutic Efficacy of Oncolytic Herpes Simplex Virus-1 with Integrin β1 Blocking Antibody OS2966.
Lee TJ; Nair M; Banasavadi-Siddegowda Y; Liu J; Nallanagulagari T; Jaime-Ramirez AC; Guo JY; Quadri H; Zhang J; Bockhorst KH; Aghi MK; Carbonell WS; Kaur B; Yoo JY
Mol Cancer Ther; 2019 Jun; 18(6):1127-1136. PubMed ID: 30926634
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic virotherapy armed with an engineered interfering lncRNA exhibits antitumor activity by blocking the epithelial mesenchymal transition in triple-negative breast cancer.
Ang L; Guo L; Wang J; Huang J; Lou X; Zhao M
Cancer Lett; 2020 Jun; 479():42-53. PubMed ID: 32200038
[TBL] [Abstract][Full Text] [Related]
10. [Construction of a new oncolytic virus oHSV2hGM-CSF and its anti-tumor effects].
Shi GL; Zhuang XF; Han XP; Li J; Zhang Y; Zhang SR; Liu BL
Zhonghua Zhong Liu Za Zhi; 2012 Feb; 34(2):89-95. PubMed ID: 22780924
[TBL] [Abstract][Full Text] [Related]
11. T-independent response mediated by oncolytic tanapoxvirus recombinants expressing interleukin-2 and monocyte chemoattractant protein-1 suppresses human triple negative breast tumors.
Suryawanashi YR; Zhang T; Woyczesczyk HM; Christie J; Byers E; Kohler S; Eversole R; Mackenzie C; Essani K
Med Oncol; 2017 Jun; 34(6):112. PubMed ID: 28466296
[TBL] [Abstract][Full Text] [Related]
12. Radiation therapy potentiates effective oncolytic viral therapy in the treatment of lung cancer.
Adusumilli PS; Stiles BM; Chan MK; Chou TC; Wong RJ; Rusch VW; Fong Y
Ann Thorac Surg; 2005 Aug; 80(2):409-16; discussion 416-7. PubMed ID: 16039175
[TBL] [Abstract][Full Text] [Related]
13. Anti-tumor effect of oncolytic herpes simplex virus G47delta on human nasopharyngeal carcinoma.
Wang JN; Hu P; Zeng MS; Liu RB
Chin J Cancer; 2011 Dec; 30(12):831-41. PubMed ID: 22059912
[TBL] [Abstract][Full Text] [Related]
14. Novel chimeric parapoxvirus CF189 as an oncolytic immunotherapy in triple-negative breast cancer.
Choi AH; O'Leary MP; Chaurasiya S; Lu J; Kim SI; Fong Y; Chen NG
Surgery; 2018 Feb; 163(2):336-342. PubMed ID: 29174433
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy.
Bourgeois-Daigneault MC; Roy DG; Aitken AS; El Sayes N; Martin NT; Varette O; Falls T; St-Germain LE; Pelin A; Lichty BD; Stojdl DF; Ungerechts G; Diallo JS; Bell JC
Sci Transl Med; 2018 Jan; 10(422):. PubMed ID: 29298865
[TBL] [Abstract][Full Text] [Related]
16. Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.
Coussy F; El Botty R; Lavigne M; Gu C; Fuhrmann L; Briaux A; de Koning L; Dahmani A; Montaudon E; Morisset L; Huguet L; Sourd L; Painsec P; Chateau-Joubert S; Larcher T; Vacher S; Melaabi S; Salomon AV; Marangoni E; Bieche I
J Hematol Oncol; 2020 Feb; 13(1):13. PubMed ID: 32087759
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic herpes viral therapy is effective in the treatment of hepatocellular carcinoma cell lines.
Song TJ; Eisenberg DP; Adusumilli PS; Hezel M; Fong Y
J Gastrointest Surg; 2006 Apr; 10(4):532-42. PubMed ID: 16627219
[TBL] [Abstract][Full Text] [Related]
18. Different Triple-Negative Breast Cancer Tumor Cell Lysates (TCLs) Induce Discrepant Anti-Tumor Immunity by PD1/PDL-1 Interaction.
Dong B; Ding Y; Huang Q; Guan X
Med Sci Monit; 2019 Jan; 25():500-515. PubMed ID: 30653481
[TBL] [Abstract][Full Text] [Related]
19. Hyperthermia potentiates oncolytic herpes viral killing of pancreatic cancer through a heat shock protein pathway.
Eisenberg DP; Carpenter SG; Adusumilli PS; Chan MK; Hendershott KJ; Yu Z; Fong Y
Surgery; 2010 Aug; 148(2):325-34. PubMed ID: 20633729
[TBL] [Abstract][Full Text] [Related]
20. Filamin A (FLNA) modulates chemosensitivity to docetaxel in triple-negative breast cancer through the MAPK/ERK pathway.
Zhao P; Ma W; Hu Z; Zang L; Tian Z; Zhang K
Tumour Biol; 2016 Apr; 37(4):5107-15. PubMed ID: 26546439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
